Phase I Study of Safety and Pharmacokinetics of Once-Daily Topical Solution in Male Subjects With Androgenetic Alopecia
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 14
- 主要终点
- Pharmacokinetic data: Cmax
研究概览
简要总结
This study will be a single center, open-label study of a single concentration of ANR- 001.1. The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7 days.
详细描述
At screening, subjects will sign informed consent and inclusion and exclusion will be reviewed for each subject. Screening data will include demographics, medical history, concomitant medications, physical examination, weight, O2 sat, vital signs laboratory evaluation (CMP, CBC, UA), and ECG.
At Day 1, a physical exam, weight, O2 sat, vital signs (including BP, pulse, respiratory rate and temperature) and review of concomitant medications will be performed, and admission criteria reviewed.
If criteria are met, the study staff will administer the first dose of study medication to the area of hair loss on the scalp (8 cm x 6 cm). If there is no hair loss the dose will be administered to the crown of the head (8 cm x 6 cm). The study staff will continue to administer the study medication to the same area of the scalp of the subject, once daily for Study Days 1, 2, 3, 4, 5, 6, and 7. Daily subject visits will include vital signs, review of adverse events and concomitant medications. PK draws and ECGs will take place at Study Days 1, 2, 7 and 8, following the first dose and the last doses, respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Males between age 18 to 65 years, in general good health. Good health is defined as a subject without any active diseases. Not included in active diseases are:
- •Migraines
- •Non-hospitalized depression o Asthma
- •Cholecystectomy
- •Gilbert's syndrome
- •Clinical diagnosis of AGA with grade II to VI hair loss on Norwood Hamilton Classification System
- •Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator's opinion, interfere with study assessments.
- •No known allergy to ANR-001.1 or any of its components.
- •Subject is willing to avoid extensive sun exposure, phototherapy, or use of tanning salon for the duration of the study.
排除标准
- •If subjects have a BMI outside of the range of 18-35kg/m2
- •Subjects using a minoxidil product (e.g., Rogaine or generic Rogaine) or a latanoprost product (e.g., Xalatan or generic Xalatan) within 30 days of the start of Day 1 of the study.
- •Subjects whose vital signs, ECG, safety labs or physical exam results are clinically significant in the opinion of the investigator.
- •Subjects have a skin condition that, in the Investigators opinion, could interfere with study assessment or put the subject at undue risk by study participation.
- •Subjects with an active or recent (within 30 days before Day 1) disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.).
- •Subjects with known or suspected hypersensitivity or allergic reaction to any of the active or inactive components of the test treatment.
- •Current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation.
研究组 & 干预措施
Primary safety and pharmacokinetic data
To obtain primary safety and pharmacokinetic data on the ANR- 001.1 when applied topically, once daily, for 7 days to the scalp
干预措施: Minoxidil (Drug)
结局指标
主要结局
Pharmacokinetic data: Cmax
时间窗: 7 days
Individual and mean maximum plasma concentration (Cmax)
Pharmacokinetic data: tmax
时间窗: 7 days
Individual and mean tmax
Pharmacokinetic data: AUC
时间窗: 7 days
Individual and mean area under the concentration-time curve calculated from time zero to the last observable concentration at time t (AUC0-t)
Pharmacokinetic data: Drug clearance
时间窗: 7 days
Individual and mean apparent clearance of drug from plasma
Safety: Systemic TEAEs
时间窗: 7 days
Incident of systemic treatment-emergent adverse events
Pharmacokinetic data: Half-life (t1/2)
时间窗: 7 days
Individual and mean half-life (t1/2)
Safety : Skin TEAEs
时间窗: 7 days
Incidence of treatment-emergent adverse events related to skin irritation at the administration site
Safety: Evaluation of QTs Interval Prolongation
时间窗: 7 days
Change from baseline in the frequency of marked QTc prolongation at each visit where ECG is performed
次要结局
未报告次要终点